Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The investigational machine has an 85% accuracy rate.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
Keytruda plus Lenvima is first approval under Project Orbis collaboration.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
pembrolizumab’s efficacy was investigated in two clinical trials of people with recurrent, locally advanced or metastatic disease.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
Could new cancer drugs restore immune responses against HIV?
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.
A genomic sequencing program revealed a genetic mutation that was able to be successfully treated with a checkpoint inhibitor.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.